# Modeling, pathogenesis and treatment of idiopathic pulmonary fibrosis

> **NIH NIH U01** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2022 · $1,262,972

## Abstract

Idiopathic pulmonary fibrosis (IPF) is an intractable interstitial lung disease characterized by fibroblastic foci,
remodeling and obliteration of alveoli, and a median survival of 3 to 4 years. The only definitive treatment is
lung transplantation, an intervention hampered by low availability of donor organs, and severe surgical and
immunological complications. Innovative approaches are therefore urgently needed. We identified three major
challenges towards improving the prognosis of IPF, and propose to address these challenges in the three
research hubs of our consortium: (1) Cell sources should be established to study pathogenesis of IPF and to
eventually prevent or reverse fibrosis. In Hub 1, we propose directed differentiation of human pluripotent stem
cells (hPSCs) into lung tissue to investigate pathogenesis and establish platforms for drug discovery. (2) Cell
removal/delivery methods are needed to either replace irreversibly damaged lung tissue, or the cells that carry
pathogenesis of IPF. In Hub 2, we will develop the necessary bioengineering modalities that will take
advantage of directed differentiation of hPSCs into lung tissue. (3) The field requires a large animal model for
the validation of pathogenetic mechanisms and preclinical validation of novel therapeutic modalities for IPF
developed by the first two research hubs. We therefore propose to establish a miniature swine model for IPF to
validate pathogenetic mechanisms discovered in Hub1, and cellular replacement approaches developed in
Hub 2. The overarching goal of this proposal is to gain desperately needed insight into the pathogenesis of IPF
(Hub 1) and to use these insights to inform the development of novel therapeutic approaches for IPF (Hub 2).
As IPF is currently an untreatable disease, it is not possible to predict which approaches will be beneficial, and
the therapy may be dictated by disease stage. Pharmacological approaches may target the fibrotic process
itself, or pathways emanating from epithelial cells that initiate this process and would likely be useful in early
stage disease or in patients that are genetically predisposed. Regenerative approaches could consist of
cellular therapies, in particular targeting ATII cells, most likely early in disease or in patients predisposed to
IPF, but may extend to transplantation of recellularized lung scaffolds in end-stage disease. Both types of
regenerative approaches will require bioengineering technologies that will be developed Hub 2 and informed
by a deeper understanding of IPF pathogenesis achieved in Hub 1. Ultimately, verification of disease
mechanism and preclinical testing of therapeutic approaches requires a large animal model, which is the focus
of Hub 3.

## Key facts

- **NIH application ID:** 10416013
- **Project number:** 5U01HL134760-07
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** HANS-WILLEM E SNOECK
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,262,972
- **Award type:** 5
- **Project period:** 2016-09-20 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10416013

## Citation

> US National Institutes of Health, RePORTER application 10416013, Modeling, pathogenesis and treatment of idiopathic pulmonary fibrosis (5U01HL134760-07). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10416013. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*